Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 26 May 2016
At a glance
- Drugs Nilotinib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NICE-BORA
- 10 Jun 2017 Biomarkers information updated
- 10 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 10 May 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.